Proximal Ventures has raised $27.5 million for its first fund, backing early-stage companies applying AI to drug development. Its founder plans to invest $500,000 to $1.5 million per start-up, placing a fresh bet on software and services for pharmaceutical work that has traditionally relied on specialist providers.
Watch Desk analysis
What happened
Sahir Raoof, a former SignalFire investor and healthcare-start-up executive, told TechCrunch that Proximal will invest at pre-seed and seed stage. The firm has already backed six start-ups, including ChronicleBio, which uses AI to analyse biological and medical data in pursuit of better understanding chronic diseases and identifying potential treatments.
Raoof’s investment thesis is that AI could automate parts of drug development and help start-ups deliver pharmaceutical services faster and at lower cost. Those are his expectations for the sector, not demonstrated results from Proximal’s portfolio.
Why it matters
Drug development involves a sprawling set of jobs, from synthesising compounds and working out how to manufacture medicines to analysing clinical-trial data. Proximal is targeting the infrastructure and services around that work, not simply betting that a bigger model will discover a drug on command. The distinction matters: pharmaceutical customers may buy practical help with costly processes long before anyone can claim AI has transformed drug discovery itself.
A $27.5 million debut fund is a relatively focused pool of capital, but the proposed cheque sizes give a clear picture of its intended reach: early backing for a handful of companies, rather than a giant fund trying to own the whole sector. Proximal’s six existing investments suggest it has started building that portfolio.
Our read
This is a concrete early-stage investment in the less glamorous plumbing of AI-enabled drug development. Raoof’s healthcare background could help with the difficult business of selling into life sciences, but a good address book is not a substitute for products that meet demanding scientific and commercial needs. The worthwhile test is whether these start-ups can show measurable improvements in real workflows, not merely promise to make pharma faster.
What to watch
- Which companies Proximal backs next, and what specific drug-development work they target.
- Whether portfolio companies can demonstrate useful results with biological, medical or clinical-trial data.
- Whether pharmaceutical customers adopt these tools and services at meaningful scale.
Discussion spark: Should AI start-ups in drug development focus first on making pharmaceutical workflows cheaper and faster, or on trying to discover treatments directly?
Sources and evidence
- Proximal Ventures raises debut fund to back startups bringing AI to drug development | TechCrunch (10 November 2026, 20:47 UTC)
- How High-Performing Engineering Teams Turn Manufacturing Data Into an Advantage|CADDi (10 November 2026, 20:47 UTC)
Watch Desk is operated by WittyWires as an independent cross-cutting AI news tracker. It does not speak for the organisations or people it covers.